Monitoring of the Safety and the Performance of the Endoscopic Cap Electrode (ECE50)

Sponsor
MED-EL Elektromedizinische Geräte GesmbH (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05245942
Collaborator
(none)
384
1
60
6.4

Study Details

Study Description

Brief Summary

The objective of this registry is to confirm the safety and the performance of the ECE50 in medical routine by collecting data.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The Endoscopic Cap Electrode (ECE50) has been designed for the delivery of electrostimulation to selected laryngeal muscles. The primary objective of this registry is to retrieve real-life data on the safety and performance of the Endoscopic Cap in medical routine. Subject's participation will last a maximum of 2 hours. Upon successful conclusion of the screening session starts the testing session of the ECE50. The ECE50 has been designed to be placed on the top of a videoendoscope for the delivery of electrostimulation to the laryngeal region. The stimulation and reaction of the muscles can provide information about the presence and type of dysfunctions and thus influence the treatment procedure. Being a registry a collection of records generated within routine medical procedures with a medical device approved for the EU market, it does not pose additional risks for the patients participating in it.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    384 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Monitoring of the Safety and the Performance of the Endoscopic Cap Electrode (ECE50)
    Actual Study Start Date :
    Dec 16, 2021
    Anticipated Primary Completion Date :
    Feb 1, 2025
    Anticipated Study Completion Date :
    Dec 16, 2026

    Outcome Measures

    Primary Outcome Measures

    1. Confirm the safety [Immediately after the intervention]

      Adverse event report analysis

    2. Assess the performance of the ECE50 [During the intervention]

      Comparison between the result of the ECE50 stimulation, Laryngeal Electromyography (LEMG), videolaryngoscopy

    Secondary Outcome Measures

    1. Standardize the medical procedure for the ECE50 [Immediately after the intervention]

      Descriptive evaluation of the ECE50 stimulation protocol

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • Legal adults (i.e., as a general rule patients ≥ 18 years old)

    • Legal adults requiring a diagnosis for a disorder that could be traced back to uni- or bilateral dysfunction of one or more laryngeal muscle(s) of the posterior cricoid region

    • Signed and dated informed consent before the start of any registry-specific procedure for all the recruited subjects

    Exclusion Criteria:
    • Lack of compliance with any inclusion criteria

    • Use of an active medical implant

    • Known allergies or intolerance to the material used for this registry

    • Parallel participation in a device/drug registry in the period of data collection, which could confound the results of the registry

    • Anything that, in the opinion of the Registry Responsible, would place the subject at increased risk or preclude the subject's full compliance with the general requirements of this registry

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Univ. Klinik für Hals-, Nasen- und Ohrenkrankheiten Vienna Austria 1090

    Sponsors and Collaborators

    • MED-EL Elektromedizinische Geräte GesmbH

    Investigators

    • Principal Investigator: Berit Schneider-Stickler, Prof.Dr.med., Univ. Klinik für Hals-, Nasen- und Ohrenkrankheiten, Vienna

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    MED-EL Elektromedizinische Geräte GesmbH
    ClinicalTrials.gov Identifier:
    NCT05245942
    Other Study ID Numbers:
    • 2021REG002
    First Posted:
    Feb 18, 2022
    Last Update Posted:
    Feb 18, 2022
    Last Verified:
    Feb 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 18, 2022